Document Detail


The dynamin inhibitors MiTMAB and OcTMAB induce cytokinesis failure and inhibit cell proliferation in human cancer cells.
MedLine Citation:
PMID:  20571068     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The endocytic protein dynamin II (dynII) participates in cell cycle progression and has roles in centrosome cohesion and cytokinesis. We have described a series of small-molecule inhibitors of dynamin [myristyl trimethyl ammonium bromides (MiTMAB)] that competitively interfere with the ability of dynamin to bind phospholipids and prevent receptor-mediated endocytosis. We now report that dynII functions specifically during the abscission phase of cytokinesis and that MiTMABs exclusively block this step in the cell cycle. Cells treated with MiTMABs (MiTMAB and octadecyltrimethyl ammonium bromide) and dyn-depleted cells remain connected via an intracellular bridge for a prolonged period with an intact midbody ring before membrane regression and binucleate formation. MiTMABs are the first compounds reported to exclusively block cytokinesis without affecting progression through any other stage of the cell cycle. Thus, MiTMABs represent a new class of antimitotic compounds. We show that MiTMABs are potent inhibitors of cancer cell growth and have minimal effect on nontumorigenic fibroblast cells. Thus, MiTMABs have toxicity and antiproliferative properties that preferentially target cancer cells. This suggests that dynII may be a novel target for pharmacologic intervention for the treatment of cancer.
Authors:
Sanket Joshi; Swetha Perera; Jayne Gilbert; Charlotte M Smith; Anna Mariana; Christopher P Gordon; Jennette A Sakoff; Adam McCluskey; Phillip J Robinson; Antony W Braithwaite; Megan Chircop
Related Documents :
7896878 - Oocyte activation and passage through the metaphase/anaphase transition of the meiotic ...
16504098 - Distinguishing between linear and exponential cell growth during the division cycle: si...
9823588 - The cell cycle: a review.
6181878 - Kinetic analysis of a split cell population following reinoculation of an ehrlich ascit...
21402698 - Suppression of latent transforming growth factor (tgf)-beta1 restores growth inhibitory...
11575448 - Impairment of gastric secretion modulation in duodenal ulcer and in long-term ppi treat...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-06-22
Journal Detail:
Title:  Molecular cancer therapeutics     Volume:  9     ISSN:  1538-8514     ISO Abbreviation:  Mol. Cancer Ther.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-07-09     Completed Date:  2010-11-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101132535     Medline TA:  Mol Cancer Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1995-2006     Citation Subset:  IM    
Copyright Information:
(c)2010 AACR.
Affiliation:
Children's Medical Research Institute, The University of Sydney, Westmead, New South Wales, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alkanes / pharmacology*
Animals
Cell Cycle / drug effects
Cell Line
Cell Line, Tumor
Cell Proliferation / drug effects*
Cell Survival / drug effects
Cytokinesis / drug effects*
Detergents / pharmacology
Dose-Response Relationship, Drug
Dynamins / antagonists & inhibitors*,  genetics,  metabolism
Fibroblasts / cytology,  drug effects,  metabolism
Flow Cytometry
GTP Phosphohydrolases / antagonists & inhibitors,  metabolism
Hela Cells
Humans
Immunoblotting
Mice
Microscopy, Fluorescence
NIH 3T3 Cells
Quaternary Ammonium Compounds / pharmacology*
RNA Interference
Trimethyl Ammonium Compounds / pharmacology*
Chemical
Reg. No./Substance:
0/Alkanes; 0/Detergents; 0/Quaternary Ammonium Compounds; 0/Trimethyl Ammonium Compounds; 0/octadecyltrimethylammonium bromide; 10182-92-0/tetradecyltrimethylammonium; EC 3.6.1.-/GTP Phosphohydrolases; EC 3.6.5.5/Dynamins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous ...
Next Document:  MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agent...